Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346890 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02346890 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 16 participants.
The verdict
NCT02346890, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.
Interventions
- DRUG AZD1722
- DRUG Renvela
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346890
The ClinicalTrials.gov registry entry for NCT02346890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD1722 is the first listed.
NCT02346890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02346890 about?
NCT02346890 is a clinical study titled "A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722". The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.
What is the current status of trial NCT02346890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT02346890?
The interventions under investigation include: AZD1722 (DRUG), Renvela (DRUG).
Who is sponsoring clinical trial NCT02346890?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.